• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HTX
Click for more information
0.00% 0.1¢

HEALTHLINX LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
HTXTrading HaltPRICE SENSITIVE01/10/09
HTXAnnual Report to shareholders25/09/09
HTXChange of Director's Interest Notice22/09/09
HTXAppendix 3B22/09/09
HTXMater Health Services partnered in ovarian cancer studyPRICE SENSITIVE11/09/09
HTXResults of Meeting10/09/09
HTXManaging Directors presentation to EGM10/09/09
HTXChange of Director's Interest Notice07/09/09
HTXAppendix 4EPRICE SENSITIVE27/08/09
HTXIndependent Experts Report accompanying NOM10/08/09
HTXNotice of Extraordinary General Meeting/Proxy Form10/08/09
HTXOvPlex outperforms CA125 by more than 60%PRICE SENSITIVE04/08/09
HTXCE approval for OvPlex ovarian cancer diagnostic testPRICE SENSITIVE30/07/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE27/07/09
HTXChange of Director's Interest Notice09/07/09
HTXCancellation of unlisted options03/07/09
HTXHealthLinx secures collaborators for major Ovplex studyPRICE SENSITIVE21/05/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/04/09
HTXCancellation of unlisted options08/04/09
HTXTop 20 securityholders and range report08/04/09
HTXChange in substantial holding06/04/09
HTXChange of Director's Interest Notice x 406/04/09
HTXReplaces Appendix 3B issued 1 April 200903/04/09
HTXChange of Director's Interest Notice02/04/09
HTXChange in substantial holding and correction of prior error02/04/09
HTXChange of Director's Interest Notice x 402/04/09
HTXAppendix 3B range report and top 20 report01/04/09
HTXChange in substantial holding26/03/09
HTXChange of Director's Interest Notice26/03/09
HTXHealthLinx announces new $3m funding facilityPRICE SENSITIVE25/03/09
HTXConversion of convertible notes23/03/09
HTXAppendix 3B23/03/09
HTXHealthLinx share purchase plan closure23/03/09
HTXLetter to Shareholders re extension of Share Purchase Plan13/03/09
HTXExtension of HTX Share Purchase Plan06/03/09
HTXAppendix 4D and Half Yearly Report and AccountsPRICE SENSITIVE25/02/09
HTXOvPlex diagnostic distribution for Singapore and SE AsiaPRICE SENSITIVE25/02/09
HTXHTX Dairy Australia study finds weight reduction compoundPRICE SENSITIVE23/02/09
HTXShare Purchase Plan offer sent to shareholders today12/02/09
HTXUK distributor to sell OvPlex in UK and IrelandPRICE SENSITIVE11/02/09
HTXShareholders Update09/02/09
HTXShare Purchase PlanPRICE SENSITIVE09/02/09
HTXIgY patent granted in EuropePRICE SENSITIVE03/02/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/01/09
HTXExpiry of unlisted options13/01/09
HTXOvPlex ovarian cancer diagnostic UK distributor licencePRICE SENSITIVE11/12/08
HTXNew diagnostic 98% accurate for early stage ovarian cancersPRICE SENSITIVE08/12/08
HTXAppendix 3Y by five03/12/08
HTXUnlisted options granted pursuant to EOOP02/12/08
HTXCancellation of 4,805 unlisted options01/12/08
HTXResults of Meeting26/11/08
HTXChairman's Address to Shareholders26/11/08
HTXAssoc Prof M Choolani joins Scientific Advisory Committee24/11/08
HTXTrading Halt
01/10/09PRICE SENSITIVE
HTXAnnual Report to shareholders
25/09/09
HTXChange of Director's Interest Notice
22/09/09
HTXAppendix 3B
22/09/09
HTXMater Health Services partnered in ovarian cancer study
11/09/09PRICE SENSITIVE
HTXResults of Meeting
10/09/09
HTXManaging Directors presentation to EGM
10/09/09
HTXChange of Director's Interest Notice
07/09/09
HTXAppendix 4E
27/08/09PRICE SENSITIVE
HTXIndependent Experts Report accompanying NOM
10/08/09
HTXNotice of Extraordinary General Meeting/Proxy Form
10/08/09
HTXOvPlex outperforms CA125 by more than 60%
04/08/09PRICE SENSITIVE
HTXCE approval for OvPlex ovarian cancer diagnostic test
30/07/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
27/07/09PRICE SENSITIVE
HTXChange of Director's Interest Notice
09/07/09
HTXCancellation of unlisted options
03/07/09
HTXHealthLinx secures collaborators for major Ovplex study
21/05/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
28/04/09PRICE SENSITIVE
HTXCancellation of unlisted options
08/04/09
HTXTop 20 securityholders and range report
08/04/09
HTXChange in substantial holding
06/04/09
HTXChange of Director's Interest Notice x 4
06/04/09
HTXReplaces Appendix 3B issued 1 April 2009
03/04/09
HTXChange of Director's Interest Notice
02/04/09
HTXChange in substantial holding and correction of prior error
02/04/09
HTXChange of Director's Interest Notice x 4
02/04/09
HTXAppendix 3B range report and top 20 report
01/04/09
HTXChange in substantial holding
26/03/09
HTXChange of Director's Interest Notice
26/03/09
HTXHealthLinx announces new $3m funding facility
25/03/09PRICE SENSITIVE
HTXConversion of convertible notes
23/03/09
HTXAppendix 3B
23/03/09
HTXHealthLinx share purchase plan closure
23/03/09
HTXLetter to Shareholders re extension of Share Purchase Plan
13/03/09
HTXExtension of HTX Share Purchase Plan
06/03/09
HTXAppendix 4D and Half Yearly Report and Accounts
25/02/09PRICE SENSITIVE
HTXOvPlex diagnostic distribution for Singapore and SE Asia
25/02/09PRICE SENSITIVE
HTXHTX Dairy Australia study finds weight reduction compound
23/02/09PRICE SENSITIVE
HTXShare Purchase Plan offer sent to shareholders today
12/02/09
HTXUK distributor to sell OvPlex in UK and Ireland
11/02/09PRICE SENSITIVE
HTXShareholders Update
09/02/09
HTXShare Purchase Plan
09/02/09PRICE SENSITIVE
HTXIgY patent granted in Europe
03/02/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
29/01/09PRICE SENSITIVE
HTXExpiry of unlisted options
13/01/09
HTXOvPlex ovarian cancer diagnostic UK distributor licence
11/12/08PRICE SENSITIVE
HTXNew diagnostic 98% accurate for early stage ovarian cancers
08/12/08PRICE SENSITIVE
HTXAppendix 3Y by five
03/12/08
HTXUnlisted options granted pursuant to EOOP
02/12/08
HTXCancellation of 4,805 unlisted options
01/12/08
HTXResults of Meeting
26/11/08
HTXChairman's Address to Shareholders
26/11/08
HTXAssoc Prof M Choolani joins Scientific Advisory Committee
24/11/08
refresh Created with Sketch. REFRESH
 

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Australian Rare Earths bullish on early-stage uranium potential at Overland, SA Australian Rare Earths has asserted it's set to launch follow up drilling after aircore results show potential uranium downhole at Overland.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.